GlassScriptPhysician profile
Kyle Matthew Smith
NPI 1093212441
$1,513.50
in general payments reported to CMS, 2019-2025
18 companies · $663 in 2025
The $663 reported for 2025 was more than what 79% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $245 · 2022: $71.92 · 2023: $297 · 2024: $236 · 2025: $663.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,196.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,196.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $440.76 | 2022-2025 | Farxiga, Breztri, Airsupra |
| Viiv Healthcare Company | $245.14 | 2021 | |
| Abbvie INC. | $232.07 | 2023-2025 | Vraylar, Ubrelvy, Qulipta |
| Amgen INC. | $120.52 | 2025 | Repatha |
| Abbott Laboratories | $115.99 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Genzyme Corporation | $49.98 | 2024-2025 | |
| Lundbeck LLC | $45.88 | 2025 | Rexulti |
| Kowa Pharmaceuticals America, INC. | $44.08 | 2022-2025 | Zoryve |
| Otsuka America Pharmaceutical, INC. | $43.21 | 2023-2025 | Rexulti |
| Novo Nordisk INC | $24.68 | 2025 | Ozempic, Rybelsus |
| Esperion Therapeutics, INC. | $23.55 | 2023 | Nexletol |
| Inspire Medical Systems, INC. | $22.42 | 2025 | Inspire |
| Antares Pharma, INC. | $21.83 | 2025 | Xyosted |
| Boston Scientific Corporation | $20.97 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $18.39 | 2025 | Dupixent |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $15.14 | 2025 | Veozah |
| Pfizer INC. | $14.87 | 2025 | |
| Ardelyx, INC. | $14.02 | 2025 | Ibsrela |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kyle Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.